WO2008015383A8 - Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer - Google Patents

Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer Download PDF

Info

Publication number
WO2008015383A8
WO2008015383A8 PCT/GB2007/002755 GB2007002755W WO2008015383A8 WO 2008015383 A8 WO2008015383 A8 WO 2008015383A8 GB 2007002755 W GB2007002755 W GB 2007002755W WO 2008015383 A8 WO2008015383 A8 WO 2008015383A8
Authority
WO
WIPO (PCT)
Prior art keywords
bmp
breast
prostate cancer
cancer therapies
therapies
Prior art date
Application number
PCT/GB2007/002755
Other languages
English (en)
Other versions
WO2008015383A2 (fr
WO2008015383A3 (fr
Inventor
Wen Guo Jiang
Original Assignee
Univ Cardiff
Wen Guo Jiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff, Wen Guo Jiang filed Critical Univ Cardiff
Publication of WO2008015383A2 publication Critical patent/WO2008015383A2/fr
Publication of WO2008015383A3 publication Critical patent/WO2008015383A3/fr
Publication of WO2008015383A8 publication Critical patent/WO2008015383A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne le rôle des protéines BMP-9 et/ou BMP-10 dans le traitement du cancer du sein ou de la prostate.
PCT/GB2007/002755 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer WO2008015383A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0615129.4A GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
GB0615129.4 2006-07-29

Publications (3)

Publication Number Publication Date
WO2008015383A2 WO2008015383A2 (fr) 2008-02-07
WO2008015383A3 WO2008015383A3 (fr) 2008-08-14
WO2008015383A8 true WO2008015383A8 (fr) 2009-07-16

Family

ID=37006438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002755 WO2008015383A2 (fr) 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer

Country Status (2)

Country Link
GB (1) GB0615129D0 (fr)
WO (1) WO2008015383A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574777C (fr) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1973559B1 (fr) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI480048B (zh) 2007-02-01 2015-04-11 Acceleron Pharma Inc 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201808334A (zh) 2007-02-09 2018-03-16 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
EP2207562B1 (fr) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Antagonistes de l'activine-actriia et utilisations pour réduire ou empêcher la sécrétion de fsh
WO2009084739A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp10
WO2009084738A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp9
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EP3345921A1 (fr) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Utilisation d'anticorps anti-actriib pour l'augmentation d'adipocytes thermogènes
ES2836534T3 (es) 2009-06-12 2021-06-25 Acceleron Pharma Inc Proteínas de fusión de ActRIIB-Fc truncadas
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2817008A1 (fr) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Agents de liaison a actriia et leurs utilisations
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN104936605A (zh) 2012-11-02 2015-09-23 细胞基因公司 激活素-actrii拮抗剂和用于治疗骨和其它病症的用途
WO2015192111A1 (fr) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Méthodes et compositions de traitement d'ulcères
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
KR102556991B1 (ko) 2014-12-03 2023-07-19 셀진 코포레이션 액티빈-ActRII 길항제 및 빈혈 치료를 위한 용도
JP7056932B2 (ja) 2015-08-25 2022-04-19 ヒスタイド アクツィエンゲゼルシャフト 組織形成誘導用化合物及びその使用
AU2016323408A1 (en) * 2015-09-17 2018-04-19 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
CA2998297A1 (fr) * 2015-09-17 2017-03-23 Histide Ag Association pharmaceutique pour convertir une cellule neoplasique en cellule non-neoplasique et ses utilisations
WO2023069447A1 (fr) * 2021-10-18 2023-04-27 The Uab Research Foundation Bmp9 ou agoniste de celui-ci et ses utilisations en rapport avec la réduction des métastases du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131087B2 (fr) * 1998-11-13 2009-04-01 Stryker Corporation Soulagement des symptomes du cancer de la prostate
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006029406A2 (fr) * 2004-09-09 2006-03-16 Stryker Corporation Methodes de traitement de tumeurs osseuses

Also Published As

Publication number Publication date
WO2008015383A2 (fr) 2008-02-07
GB0615129D0 (en) 2006-09-06
WO2008015383A3 (fr) 2008-08-14

Similar Documents

Publication Publication Date Title
WO2008015383A3 (fr) Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer
WO2008076278A3 (fr) Procédés de traitements
IL184617A0 (en) Dr5 antibodies and uses thereof
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
EP2173740A4 (fr) Inhibiteurs de l'hème-oxygénase et leur utilisation dans le traitement du cancer et de maladies du système nerveux central
WO2009053041A3 (fr) Identification de marqueurs associés aux tumeurs à des fins de diagnostic et de thérapie
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2008150530A3 (fr) Molécules de liaison de cripto
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2007100920A3 (fr) Diagnostic et traitement du cancer de la prostate
MX2012001513A (es) Uso de melanocortinas para tratar la dislipidemia.
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
WO2009074253A3 (fr) Dérivés de phospholipide de clofarabine
WO2009046123A3 (fr) Antagonistes de nlrr-1 et leurs utilisations
WO2008061048A3 (fr) Procédés et compositions permettant de diagnostiquer et de traiter le cancer de la prostate
WO2008009895A3 (fr) Matriptase-2
WO2008092103A3 (fr) Traitements de cancer par combinaison comprenant de l'elsamitrucine et d'autres agents
ZA200810524B (en) Pyrimidine derivatives useful in the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2